
## MANAGEMENT OF PROSTAGLANDIN-ASSOCIATED PERIORBITOPATHY SYNDROME (PAPS)



1. PAPS Compendium Expert Advisory Meeting, 23rd July, 2022; 2. Sakata et al. Semin Ophthalmol 2021;37:447–54; 3. Asia-Pacific Glaucoma Society. Asia Pacific Glaucoma Guidelines, 3rd Edition. 2016; 4. Miki et al. PLoS One 2017;12:e0181550. IOP: intraocular pressure; PAPS: prostaglandin-associated periorbitopathy syndrome; PGA: prostaglandin analogue.







## Advisory on proper eyedrop instillation technique

Patients are advised to carefully clean any excess eyedrops from the periorbital area. Practical recommendations may include:<sup>1</sup>

- Washing off excess medication
- Cleaning with a wet wipe
- Using a tissue to gently absorb spilled eyedrops



Wiping spilled eyedrops with a tissue may spread medication to the lower eyelid and exacerbate certain side-effects of PGAs, which may potentially contribute towards PAPS.<sup>1,2</sup> In addition, some ophthalmologists have anecdotally suggested that older patients often administer PGAs before bed in the supine position, which could increase their risk of PAPS (e.g., patients may fall asleep without washing off excess medication).<sup>2</sup>

Drug class	Dosage <sup>3</sup>	Efficacy (IOP reduction) <sup>3</sup>
PGAs	OD	25–35%
Prostanoid EP2 receptor agonists	OD <sup>4</sup>	15–35%4
β-Blockers	OD-BD	20–25%
a <sub>1</sub> -Blockers	BD	15–20%
a <sub>2</sub> -Agonists	BD-TDS	18–25%
$\alpha_1\beta$ -Blockers	BD	20%
Topical carbonic anhydrase inhibitors	BD-TDS	20%
Systemic carbonic anhydrase inhibitors	BD-QDS	30–40%
Rho-kinase inhibitors	OD-BD <sup>5,6</sup>	20–25% <sup>7</sup>
Cholinergics	TDS-QDS	20–25%

## Dosing frequency and reported efficacy of various anti-glaucoma drug classes

 Inoue. Clin Ophthalmol 2014;8:903–13; 2. PAPS Compendium Expert Advisory Meeting, 23<sup>rd</sup> July, 2022; 3. Asia-Pacific Glaucoma Society. Asia Pacific Glaucoma Guidelines, 3<sup>rd</sup> Edition. 2016; 4. EYBELIS™ (Omidenepag isopropy)) ophthalmic solution 0.002%. Prescribing Information. Santen Pharmaceutical Co., Ltd. 2019; 5. GLANATEC<sup>®</sup> (Ripasudii) ophthalmic solution 0.4%. Prescribing information. Kowa Company, Ltd. 2020; 6. RHOPRESSA<sup>®</sup> (Netarsudi) ophthalmic solution 0.02%. Prescribing Information. Aerie Pharmaceuticals, Inc. 2019; 7. European Glaucoma Society. Terminology and Guidelines for Glaucoma, 5<sup>th</sup> Edition. 2021. BD: twice daily; EP2: prostaglandin E2; IOP: intraocular pressure; OD: once daily; PAPS: prostaglandin-associated periorbitopathy syndrome; PGA: prostaglandin analogue; QDS: four times daily; TDS: thrice daily.

